Equity · Healthcare
BLTE
NASDAQBelite Bio, Inc
$143
−5.92% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 16, 2026
Price · Chart
$200
$140
21 Jul
16 Oct
The line runs $161 on 21 July through $143 on 16 October, on a scale from $140 to $200. Days the market did not trade hold the previous close, flat.
52-week range
$78.58 – $194
Avg volume
11.5K
as of Oct 16, 2026
Filings 3 sets
BLTE reported financials
SEC EDGARBLTE reported net income of −$77.6M for the fiscal year ended 31 Dec 2025.
Figure
Reported
Period
Net income
−$77.6M
31 Dec 2025
fiscal year
Diluted EPS
−$2.31
31 Dec 2025
fiscal year
Total assets
$780.6M
31 Dec 2025
at period end
Total equity
$770.5M
31 Dec 2025
at period end
BLTE institutional holders
SEC EDGAR7 of the 45 institutional funds we track reported a BLTE position for the quarter ended 30 Jun 2026 — a combined $204.5M; the latest of those filings landed 02 Sep 2026.
Fund
Action
Shares
Value
BLTE fails-to-deliver
SECOn 23 Sep 2026, 54 shares of BLTE failed to deliver (about $9K).
Settlement date
Shares failed
Notional
% of shares out
23 Sep 2026
54
$9K
<0.001%
08 Sep 2026
10,744
$2.1M
0.027%
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 31 Dec 2025
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data